-
EP4048278
European procedure
Extract from the Register of European Patents
EP About this file: EP4048278
| EP4048278 - METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DIONE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 06.09.2024 Database last updated on 09.04.2026 | |
| Former | The patent has been granted Status updated on 29.09.2023 | ||
| Former | Grant of patent is intended Status updated on 18.05.2023 | ||
| Former | Request for examination was made Status updated on 29.07.2022 | ||
| Former | The international publication has been made Status updated on 01.05.2021 | ||
| Former | unknown Status updated on 24.11.2020 | Most recent event Tooltip | 06.09.2024 | No opposition filed within time limit | published on 09.10.2024 [2024/41] | Applicant(s) | For all designated states Celgene Corporation Route 206 & Province Line Road Princeton, NJ 08543 / US | [2024/14] |
| Former [2022/35] | For all designated states Celgene Corporation 86 Morris Avenue Summit, NJ 07901 / US | Inventor(s) | 01 /
ANTON, Maria Soraya, Carrancio c/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121 / US | 02 /
BUCHHOLZ, Tonia J. c/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185 / US | 03 /
KASIBHATLA, Shailaja c/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121 / US | 04 /
LOPEZ-GIRONA, Antonia c/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121 / US | 05 /
NARLA, Rama, Krishna c/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121 / US | 06 /
POURDEHNAD, Michael c/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185 / US | [2022/35] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2022/35] | Application number, filing date | 20807558.0 | 20.10.2020 | [2022/35] | WO2020US56408 | Priority number, date | US201962924028P | 21.10.2019 Original published format: US 201962924028 P | [2022/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021080935 | Date: | 29.04.2021 | Language: | EN | [2021/17] | Type: | A1 Application with search report | No.: | EP4048278 | Date: | 31.08.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.04.2021 takes the place of the publication of the European patent application. | [2022/35] | Type: | B1 Patent specification | No.: | EP4048278 | Date: | 01.11.2023 | Language: | EN | [2023/44] | Search report(s) | International search report - published on: | EP | 29.04.2021 | Classification | IPC: | A61K31/5377, A61P35/00 | [2022/35] | CPC: |
A61P35/00 (EP,IL,KR);
A61K31/5377 (EP,IL,KR,US);
A61K9/0053 (IL,KR,US);
A61P35/02 (KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/35] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | VERFAHREN ZUR BEHANDLUNG HÄMATOLOGISCHER MALIGNOME MIT 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DION | [2022/35] | English: | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DIONE | [2022/35] | French: | PROCÉDÉS DE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES À L'AIDE DE 2-(2,6-DIOXOPIPÉRIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZÉTIDIN-1-YL)MÉTHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DIONE | [2022/35] | Entry into regional phase | 20.04.2022 | National basic fee paid | 20.04.2022 | Designation fee(s) paid | 20.04.2022 | Examination fee paid | Examination procedure | 20.04.2022 | Examination requested [2022/35] | 20.04.2022 | Date on which the examining division has become responsible | 02.12.2022 | Amendment by applicant (claims and/or description) | 19.05.2023 | Communication of intention to grant the patent | 25.09.2023 | Fee for grant paid | 25.09.2023 | Fee for publishing/printing paid | 25.09.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 02.08.2024 | No opposition filed within time limit [2024/41] | Fees paid | Renewal fee | 03.05.2022 | Renewal fee patent year 03 | 13.09.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YP] WO2019209692 (CELGENE CORP et al.) | [YP] WO2020210418 (CELGENE CORP et al.) | by applicant | US201962924028 | RAJKUMAR ET AL., NATURE REVIEWS CLINICAL ONCOLOGY, vol. 11, 2014, pages 628 - 630 | "Remington's Pharmaceutical Sciences,", 1990, MACK PUBLISHING | "Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING | JACQUES, J. ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY-INTERSCIENCE | WILEN, S. H. ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 | ELIEL, E. L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL | WILEN, S. H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 | TODD, M.: "Separation Of Enantiomers : Synthetic Methods", 2014, WILEY-VCH VERLAG GMBH & CO. KGAA | TODA, F.: "Enantiomer Separation: Fundamentals and Practical Methods", 2007, SPRINGER SCIENCE & BUSINESS MEDIA | SUBRAMANIAN, G.: "Chiral Separation Techniques: A Practical Approach", 2008, JOHN WILEY & SONS | AHUJA, S.: "Chiral Separation Methods for Pharmaceutical and Biotechnological Products", 2011, JOHN WILEY & SONS |